A trial of decitabine and ECF chemotherapy for advanced cancer of the food pipe (oesophageal cancer)

Cancer type:

Oesophageal cancer

Status:

Results

Phase:

Phase 1

This trial was looking at a drug called decitabine in combination with ECF chemotherapy for advanced cancer of the food pipe (oesophageal cancer).

Doctors often treat oesophageal cancer with chemotherapy and surgery. One of the most common types of chemotherapy for oesophageal cancer is a combination of drugs called ECF. This is the chemotherapy drugs epirubicin, cisplatin and fluorouracil (5FU).

In this trial, doctors wanted to see if another drug called decitabine, made ECF work better. Decitabine works by changing the activity of some of the genes in the cancer cells. This may make the cells more sensitive to ECF. Doctors hoped that adding this new drug would make ECF more effective.

The aims of the trial were to find out

  • The best dose of decitabine to give
  • What the side effects were
  • How well decitabine and ECF worked together

Summary of results

Despite attempting to contact the trial team, we have been unable to get any results for this trial.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Mark Middleton

Supported by

Experimental Cancer Medicine Centre (ECMC)
MGI Pharma Inc

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 739

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page